Core Insights - Neurocrine Biosciences Inc. announced data from its Phase 3 KINECT-DCP study evaluating valbenazine for dyskinetic cerebral palsy (DCP) [1] - The trial did not meet its primary or key secondary endpoints, which aimed to assess improvement in chorea among DCP patients [3][4] - Analyst commentary indicates that while the recent trial results are disappointing, they do not significantly impact the company's valuation or investment thesis [5] Study Details - The KINECT-DCP study involved participants aged six to 70 years who were randomized to receive either valbenazine or a placebo for 14 weeks [3] - Following the initial phase, participants had the option to enter an open-label extension phase where all received valbenazine [4] - Adverse events reported were consistent with the established safety profile of valbenazine [4] Market Reaction - Neurocrine Biosciences shares experienced a decline of 1.55%, trading at $145.24 during premarket hours [6] - Analysts expect investor focus to shift towards execution and commercial performance in 2026, with limited near-term clinical catalysts [5]

Core Insights - Merck announced positive results from the Phase 3 HYPERION trial for WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH) [1] Group 1 - The trial evaluated WINREVAIR versus placebo, both in combination with background therapy [1] - The study focused on recently diagnosed adults with PAH classified as WHO Group 1, functional class II or III, at intermediate or high risk of disease progression [1] - WINREVAIR demonstrated a reduction in the risk of clinical worsening in the trial participants [1]